Article Information
- Received March 7, 2011
- Revision received March 22, 2011
- Accepted March 26, 2011
- First published May 11, 2011.
- Version of record published May 11, 2011.
Author Information
Author contributions
Author contributions: T.H.J., S.H.F., M.J.P., P.H., and J.M.B. designed research; P.H., T.H.J., K.D.L., M.G.R., and J.B.K. performed research; P.H., K.D.L., M.J.P., and J.M.B. analyzed data; P.H., M.J.P., and J.M.B. wrote the paper.
Disclosures
- Received March 7, 2011.
- Revision received March 22, 2011.
- Accepted March 26, 2011.
This work was supported by the Cure Parkinson Trust and the Krembil Neuroscience Fund. P.H. was supported by fellowships from the Edmond J. Safra Philanthropic Foundation and the Parkinson Society Canada. K.D.L. was the recipient of an Australian Postgraduate Award.
The authors declare no competing financial interests. S.H.F. has received consultancy and speaker fees from Acadia, Asubio, Merz, Novartis, Teva, and Biovail. T.H.J. and J.B.K. have received consultancy fees from Atuka Ltd. J.M.B. has received consultancy fees from and holds an equity position in Atuka Ltd. All other authors have no financial disclosures.
- Correspondence should be addressed to Jonathan M. Brotchie, Toronto Western Research Institute, McLaughlin 11-419, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. brotchie{at}uhnres.utoronto.ca
Online Impact
